Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510419 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack
A Phase 3 study of Migraine, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 73
- Enrollment target
- 10
- Study locations
NCT00510419: Completed Phase 3 study of Migraine, sponsored by Pfizer.
NCT00510419 is a Phase 3 study of Migraine that has completed, run by Pfizer. The registered enrollment target is 73 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (80% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00510419, a Phase 3 study of Migraine, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 73 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this research study is to evaluate an investigational auto-injector system for delivering sumatriptan under the skin for a single migraine attack. The study could take approximately 5 weeks and will include about 3 office visits to the study doctor, the patient will be contacted every 2 weeks until the patient experiences a migraine and uses the auto-injector. The last visit will be done by a telephone follow-up call.
Conditions Studied
Interventions
- DRUG "Investigational"Auto-injector (sumatriptan succinate)
Study Locations (10)
Texas
- Anodyne Headache and Pain Care - Dallas
- Houston Headache Clinic - Houston
- Road Runner Research, LTD - San Antonio
California
- San Francisco Clinical Research Center - San Francisco
Connecticut
- New England Center for Headache - Stamford
Illinois
- Diamond Head Clinic - Chicago
Michigan
- Michigan Head Pain & Neurological Institute - Ann Arbor
Missouri
- Clinvest - Springfield
Pennsylvania
- University of Pittsburgh Headache Center - Pittsburgh
Tennessee
- Wesley Headache Clinic - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2007-07 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
What the finished NCT00510419 record still lists
NCT00510419 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which "Investigational"Auto-injector (sumatriptan succinate) is the first listed.
NCT00510419 lists 10 locations in 8 states (Texas, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT00510419 about?
NCT00510419 is a clinical study titled "A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack". The purpose of this research study is to evaluate an investigational auto-injector system for delivering sumatriptan under the skin for a single migraine attack. The study could take approximately 5 weeks and will include about 3 office visits to the study doctor, the patient will be contacted ever...
What is the current status of trial NCT00510419?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 73 participants. The study started on 2007-07. Estimated completion is 2007-12.
What conditions does trial NCT00510419 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT00510419?
The interventions under investigation include: "Investigational"Auto-injector (sumatriptan succinate) (DRUG).
Who is sponsoring clinical trial NCT00510419?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00510419 being conducted?
This trial has 10 study locations across California, Connecticut, Illinois, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00510419's enrollment target sits among peer trials
73 69th of 102 higher than 34 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia